BENEVOLENTAI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.56 EUR | -3.45% |
|
-12.50% | -48.15% |
| May. 02 | Benevolentai S.A. Announces Directorate Changes | CI |
| Apr. 15 | BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 64M 79.82M 74.33M | Sales 2025 * | 38M 47.39M 44.13M | Capitalization | 60.78M 75.81M 70.59M |
|---|---|---|---|---|---|
| Net income 2024 * | 2M 2.49M 2.32M | Net income 2025 * | -19M -23.7M -22.07M | EV / Sales 2024 * | 0.42 x |
| Net cash position 2024 * | 33.75M 42.1M 39.2M | Net cash position 2025 * | 170M 212M 198M | EV / Sales 2025 * | -2.88 x |
| P/E ratio 2024 * |
23.6
x | P/E ratio 2025 * |
-6.84
x | Employees | 248 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.04% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.69% | ||
| 1 week | -9.38% | ||
| Current month | -9.38% | ||
| 1 month | -20.55% | ||
| 3 months | -14.71% | ||
| 6 months | -22.15% | ||
| Current year | -46.30% |
1 week
0.54
0.64
1 month
0.540.74
Current year
0.541.41
1 year
0.482.66
3 years
0.4810.00
5 years
0.4810.00
10 years
0.4810.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ivan Griffin
FOU | Founder | 48 | 13-10-31 |
Catherine Isted
DFI | Director of Finance/CFO | - | 23-09-10 |
| Chief Tech/Sci/R&D Officer | - | 20-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nigel Shadbolt
BRD | Director/Board Member | 68 | 20-06-30 |
Jean Raby
BRD | Director/Board Member | 60 | 22-04-21 |
John Orloff
BRD | Director/Board Member | 66 | 21-08-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 0.56 | -3.45% | 1 245 |
| 24-05-07 | 0.58 | -1.69% | 27,392 |
| 24-05-06 | 0.59 | -4.22% | 8,110 |
| 24-05-03 | 0.616 | -3.75% | 24,299 |
| 24-05-02 | 0.64 | 0.00% | 37,817 |
Real-time Euronext Amsterdam, May 07, 2024 at 10:31 am EDT
More quotes
BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery. The Company serves patients by leveraging its proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery.
The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, and advancing in-house pipelines to inflection points.
Calendar
2024-09-23
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.4985
GBP
Average target price
1.632
GBP
Spread / Average Target
+227.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.30% | 76.24M | |
| +21.74% | 46.4B | |
| -0.97% | 41.75B | |
| +49.17% | 41.37B | |
| -3.52% | 29.71B | |
| +11.12% | 26.01B | |
| -19.37% | 19.52B | |
| +31.18% | 12.43B | |
| -0.04% | 12.13B | |
| +0.39% | 12.18B |
- Stock Market
- Equities
- BAI Stock